Woodline Partners’s Zentalis Pharmaceuticals ZNTL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $615K | Hold |
530,582
| – | – | ﹤0.01% | 839 |
|
|
2025
Q1 | $844K | Hold |
530,582
| – | – | 0.01% | 781 |
|
|
2024
Q4 | $1.61M | Sell |
530,582
-524,700
| -50% | -$1.59M | 0.01% | 688 |
|
|
2024
Q3 | $3.88M | Sell |
1,055,282
-461,795
| -30% | -$1.7M | 0.03% | 415 |
|
|
2024
Q2 | $6.2M | Buy |
1,517,077
+80,051
| +6% | +$327K | 0.06% | 313 |
|
|
2024
Q1 | $22.6M | Buy |
1,437,026
+33,473
| +2% | +$528K | 0.21% | 149 |
|
|
2023
Q4 | $21.3M | Buy |
1,403,553
+403,553
| +40% | +$6.11M | 0.23% | 130 |
|
|
2023
Q3 | $20.1M | Sell |
1,000,000
-94,974
| -9% | -$1.91M | 0.24% | 129 |
|
|
2023
Q2 | $30.9M | Sell |
1,094,974
-1,070,577
| -49% | -$30.2M | 0.37% | 75 |
|
|
2023
Q1 | $37.2M | Buy |
2,165,551
+2,019,032
| +1,378% | +$34.7M | 0.51% | 45 |
|
|
2022
Q4 | $2.95M | Sell |
146,519
-173,228
| -54% | -$3.49M | 0.04% | 418 |
|
|
2022
Q3 | $6.93M | Buy |
319,747
+138,475
| +76% | +$3M | 0.1% | 245 |
|
|
2022
Q2 | $5.09M | Buy |
181,272
+140,524
| +345% | +$3.95M | 0.08% | 258 |
|
|
2022
Q1 | $1.88M | Sell |
40,748
-327,425
| -89% | -$15.1M | 0.03% | 399 |
|
|
2021
Q4 | $30.9M | Sell |
368,173
-139,674
| -28% | -$11.7M | 0.44% | 48 |
|
|
2021
Q3 | $33.8M | Buy |
507,847
+2,172
| +0.4% | +$145K | 0.55% | 41 |
|
|
2021
Q2 | $26.9M | Buy |
505,675
+361,514
| +251% | +$19.2M | 0.5% | 50 |
|
|
2021
Q1 | $6.26M | Buy |
144,161
+4,161
| +3% | +$181K | 0.14% | 170 |
|
|
2020
Q4 | $7.27M | Buy |
140,000
+2,116
| +2% | +$110K | 0.19% | 138 |
|
|
2020
Q3 | $4.51M | Buy |
137,884
+94,158
| +215% | +$3.08M | 0.15% | 135 |
|
|
2020
Q2 | $2.1M | Buy |
+43,726
| New | +$2.1M | 0.08% | 133 |
|